In October 2000, 71,187 @entity1 were treated for @entity3754 using @entity3753 and @entity6566 ( @entity6567 ) or @entity6567 alone in Leogane, Haiti. We documented the frequency of adverse reactions, severity and cost of treatment. Adverse reactions were classified as minor, moderate, or severe. Overall, 24% (17,421) of the treated @entity1 reported one or more adverse reactions. There were 15,916 (91%) minor and 1502 (9%) moderate adverse reaction reports. @entity1 outnumbered @entity1 2:1 in reporting moderate problems. Three @entity1 , representing roughly one in 25,000 @entity1 treated, were hospitalized with severe adverse reactions judged to be treatment-associated by physician review. The cost per @entity1 treated for adverse reactions was more than twice the cost per @entity1 treated for @entity3754 (dollar 1.60 versus dollar 0.71). Severe adverse reactions to @entity3754 treatment using @entity6567 with or without @entity3753 are uncommon. Minor and moderate reactions are more commonly reported and their management represents a challenge to @entity3754 elimination programs.

Frequency, severity, and costs of adverse reactions following mass treatment for XXXX using @entity6566 and @entity3753 in Leogane, Haiti, 2000.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Men', 'person', 'persons'] @entity3753 :: ('MESH:D015766', 'Chemical') :: ['albendazole'] @entity6566 :: ('MESH:D004049', 'Chemical') :: ['diethylcarbamazine'] @entity6567 :: ('CHEBI:23580', 'Chemical') :: ['DEC'] @entity3754 :: ('MESH:D004605', 'Disease') :: ['lymphatic filariasis']
@entity3754 :: (MESH:D004605,Disease) :: ['lymphatic filariasis']
